UNIVERSITY OF MINNESOTA

ISP-001 trial shows positive results in MPS I patient with pharmacodynamic and functional improvements, no adverse events reported. Data presentation scheduled for October 14, 2024.

USDA launches Distressed Borrowers Assistance Network to provide personalized support to financially distressed farmers and ranchers, connecting them with individualized assistance through Cooperative Agreements and partnerships with organizations like Farm Aid and universities.

Franco, a clinical trial participant, faces organ inflammation from experimental medication, highlighting issues in Canada's clinical trial industry where participants, often economically desperate, are incentivized to lie about side effects to complete studies for full payment. Canada leads G7 nations in clinical trials per capita but lacks robust oversight, fostering a subculture of deception among participants. Health Canada aims to align with international best practices by 2025, but current oversight is limited, with only a fraction of trials inspected annually. Participants like Franco, lured by high compensation, often conceal health issues and side effects, risking their health and compromising study data integrity.

Bioxytran's Prolectin-M drug, validated in a peer-reviewed article, blocks galectins to prevent viral entry, potentially impacting $147 billion vaccination and antiviral markets. The study using NMR spectroscopy revealed galectin-3's role in viral attachment to human cells, suggesting broad-spectrum antiviral potential.

Rwanda began vaccinating high-risk individuals against mpox, receiving 1,000 doses. The campaign targets 7 districts bordering the DRC, focusing on truck drivers and sex workers. Africa reported 2,912 new cases last week, with 14 deaths. The Global Fund pledged $9.5 million to the DRC. Japan and the DRC finalized a plan for Japan to donate 3 million mpox vaccine doses, administered by dermal scarification.

USC's Keck School of Medicine launches a $2.7 million NIH-funded, multi-site study to understand how type 1 diabetes affects brain development in children, aiming to refine clinical guidelines and therapeutic approaches.

Ranil Wickramasinghe, distinguished professor in Chemical Engineering, will present a seminar on 'Development of membrane-based operations for emerging separations challenges' on Sept. 20, 4-5 p.m. in CHEM 144. Refreshments available from 3:30 p.m. in CHEM 145. Free and open to the public.

FDA clears Turing Medical's Bullsai Identify, an AI-driven brain mapping tech for personalized neuromodulation therapy in Parkinson's disease, aiming to enhance treatment precision and reduce side effects.

Liraglutide (Saxenda) helped obese children aged 6-11 lower BMI and reach healthier weight, per a study in the New England Journal of Medicine. The drug, safe but with side effects like nausea, showed a 5.8% BMI drop in the liraglutide group vs. a 1.6% increase in the placebo group, though BMI rose again post-medication cessation. Experts suggest its potential for long-term health benefits despite current costs and need for further long-term studies.

A study shows liraglutide, combined with diet and exercise, is safe and effective for kids aged 6-11, reducing BMI and improving health markers. Novo Nordisk seeks US approval for this age group, aiming to treat common childhood obesity. Side effects, mainly gastrointestinal, were common but mostly mild. Experts emphasize careful consideration of risks and long-term effects.